JAK Inhibitors Reshaped Alopecia Areata Care, but Long-Term Data Gaps Remain

For decades, people with alopecia areata had few options beyond corticosteroids and contact sensitizers that often failed to produce lasting hair regrowth, leaving many patients to disengage from care altogether.

A review published in the Journal of Inflammation Research argued that this landscape has shifted dramatically with the arrival of Janus kinase (JAK) inhibitors but cautioned that the field now needs robust real-world evidence to understand how these therapies perform outside the controlled environment of clinical trials.¹

Disease Burden Extends Beyond Hair Loss

Alopecia areata is a non-scarring autoimmune hair loss condition driven by cytotoxic T-cell attacks on the hair follicle that disrupt the normal growth cycle. It carries a lifetime incidence of roughly 2% in the UK and disproportionately affects women, people from Asian and other ethnic groups with darker skin tones, and those in lower socioeconomic brackets.

Although hair loss has historically been dismissed as cosmetic, the review's authors emphasized that it contributes to reduced quality of life, higher rates of anxiety and depression, and increased unemployment, with the condition ranked above both melanoma and psoriasis in global years lost to disability.

Those disparities were quantified in a 2024 population-based cohort study published in the British Journal of Dermatology that identified 6961 people who developed alopecia areata between 2009 and 2018 using the UK Oxford–Royal College of General Practitioners Research and Surveillance Centre database.² People of Asian ethnicity had a lifetime incidence of 5.87%, compared with 1.7% in White individuals, and those in the most-deprived socioeconomic quintile were nearly twice as likely to develop the condition as those in the least-deprived group. People with alopecia areata of Black ethnicity were most likely to develop anxiety within 2 years of diagnosis and had the greatest risk of work absences, underscoring why demographic representation remains a priority in registry design.

Three JAK Inhibitors Now Carry Regulatory Approval

The present review outlined data behind the 3 JAK inhibitors currently licensed for alopecia areata: baricitinib (Olumiant; Eli Lilly and Company), ritlecitinib (Litfulo; Pfizer), and deuruxolitinib (Leqselvi; Sun Pharma).¹

In the BRAVE-AA1 and BRAVE-AA2 trials (NCT03570749; NCT03899259) of baricitinib, 38.8% of patients on the 4-mg dose achieved a Severity of Alopecia Tool (SALT) score of 20 or less at week 36, compared with 6.2% of those on placebo. The ALLEGRO trial (NCT03732807) of ritlecitinib showed that 14% to 31% of treated patients reached this same end point at week 24, against 2% of placebo recipients. Deuruxolitinib, evaluated in the THRIVE-AA1 trial (NCT04518995) among others, produced response rates of 29.6% to 41.5% depending on the dose, compared with 0.8% with placebo.

Across all 3 agents, the authors noted a consistent dose-response relationship, with higher doses driving better efficacy but also carrying greater risk of adverse events such as elevated lipids, decreased hemoglobin, and, in the case of deuruxolitinib, thromboembolic events that were more frequent at the higher 12-mg twice-daily dose.

Real-World Data Carries Distinct Value

The authors stressed that randomized controlled trials, while necessary for licensing, are not designed to capture rare or long-term adverse events, given their short duration and restrictive eligibility criteria. They pointed to the 2009 withdrawal of efalizumab for psoriasis, after post-marketing surveillance uncovered multifocal leukoencephalopathy cases not identified during trials, as a cautionary example.

Existing real-world data for alopecia areata JAK inhibitors largely come from small, retrospective, single-center cohorts that confirm trial findings but cannot address questions around dose reduction, treatment cessation, or long-term safety.

A New Global Registry Effort

To address these gaps, the review introduced the Global Register of Alopecia Areata Disease Severity and Treatment Safety (GRASS)-UK, a prospective multicenter pharmacovigilance register hosted at the University of Manchester and managed by the British Association of Dermatologists.

Currently in a pilot phase at 2 sites, GRASS-UK will expand to roughly 15 specialist hair centers. It is part of a broader international network, GRASS-International, already active in Australia, Italy, and Ireland, with more than 1000 patients enrolled. The authors framed this infrastructure as comparable in ambition to the British Association of Dermatologists Biologics and Immunomodulators Register, which has shaped psoriasis guidelines for nearly 2 decades.

The authors wrote that "a global consensus is emerging that appreciates the need for prospective high-quality [real-world data] designed to achieve a truly comprehensive assessment of treatment safety and effectiveness" in alopecia areata.

As a narrative rather than systematic review, the article did not apply formal quality-grading criteria to the studies it summarized, and several cited real-world cohorts were limited by small sample sizes and the absence of control groups. The authors also acknowledged that disease registers are vulnerable to channeling bias, since treatment selection in practice is driven by disease severity and comorbidities rather than randomization.

References

1. Khoda F, Chandidzura A, Sinclair R, Wall D, Meah N, Harries M. Real world evidence in alopecia areata: current management, emerging therapies and future challenges – a narrative review. J Inflamm Res. 2026;19:540843. doi:10.2147/JIR.S540843
2. Thompson AR, Tziotzios C, Nesnas J, Randall R, Czachorowski M, Messenger AG. Lifetime incidence and healthcare disparities in alopecia areata: a UK population-based cohort study. Br J Dermatol. 2024;191(6):924-935. doi:10.1093/bjd/ljae307